Cannabis Science Inc. (CBIS); A Stock to Watch in the Highly Controversial Medical Marijuana Industry

Share On Facebook
share on Linkedin

Cannabis Science Inc. (OTC:CBIS), a development-stage company engaged in the development, production and commercialization of phytocannabinoid-based pharmaceutical products, is an emerging company in the highly controversial medical marijuana industry.

Based in Denver, Colorado, CBIS has made some steady progress this year, and this reflects in the company’s shares’ performance in 2012. Year-to-date, CBIS shares have gained a whopping 585.71%. On Wednesday, the stock closed 2.86% higher at $0.0720.

According to a 10Q filing made by Cannabis Science recently, the company signed a license agreement with Apothecary Genetics Investments LLC in February this year to produce several CBIS Brand Formulations for the California medical cannabis market. Under the terms of the agreement, Apothecary will also provide research and development facilities with full circle operations.

CBIS also acquired GGECO University Inc. in February this year. GGECO is an online video-based medical cannabis education system, providing courses on medical cannabis law, the benefits of medical marijuana, cooking, horticulture and bud tending. In March this year, CBIS also acquired Cannabis Consulting Inc.

The 10Q filing from CBIS showed that the company’s license revenue for the three-month period ended March 31, 2012 was $25,000, compared with $11,290 reported for the same period last year.

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Leave A Reply

 
Do you want to write for our Newspaper? Get in touch: newspaper@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201124 17:11:05